PKC412
Drug
Novartis Pharma AG
Total Payments
$17,476
Transactions
9
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $12,214 | 4 | 3 |
| 2017 | $5,262 | 5 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,253 | 5 | 98.7% |
| Travel and Lodging | $181.03 | 1 | 1.0% |
| Food and Beverage | $42.00 | 3 | 0.2% |
Top Doctors Receiving Payments for PKC412
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Boston, MA | $8,161 | 3 |
| , M.D | Internal Medicine | Baltimore, MD | $7,999 | 3 |
| , M.D./PH.D | Student in an Organized Health Care Education/Training Program | Stanford, CA | $1,316 | 3 |
Ad
Manufacturing Companies
- Novartis Pharma AG $17,476
Product Information
- Type Drug
- Total Payments $17,476
- Total Doctors 3
- Transactions 9
About PKC412
PKC412 is a drug associated with $17,476 in payments to 3 healthcare providers, recorded across 9 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $12,214 was paid across 4 transactions to 3 doctors.
The most common payment nature for PKC412 is "Consulting Fee" ($17,253, 98.7% of total).